2.

INTRODUCTION

Company, Future Strategy overview – Johan Wäborg

Introduction to Iconovo

Platform & project overview

Our business model

Sustainability targets

Our new strategy

3.

INHALATION GENERICS

Generics business – Dr Orest Lastow, Roger Lassing

ICOpre
• Unveiling the fourth inhaler platform
• New generic platform
• Addressable market & competition
ICOres
• Our flagship inhaler for inhaled generics
• Addressable market and competition
• Then new agreement with Amneal
ICOcap
• Our collaboration with Stevanato Group
• Addressable market & competition

4.

INNOVATIVE INHALATION PROJECTS

Inhaled Innovation – Dr Orest Lastow, Roger Lassing

ICOone platform
Unmet medical need addressed by inhalation therapy
• Inhaled oxytocin in PPH – Monash University (Pete Lambert)
• Inhaled covid-19 vaccine – ISR (Professor Ola Winqvist)
Introducing the opportunities
• Lung as target
• Fast onset of action
• Replacing injection
Project status
• Addressable market for inhaled innovation

Roundtable discussion with Q&A

5.

ICONOVO PHARMA

Johan Wäborg, Anna Gallon

Generic Nordics sales organisation – rationale
Go-to-market model
Product portfolio and unique position
Setup of Iconovo Pharma

The market opportunity
• Addressable market
• Financial Targets and Timelines

Roundtable discussion with Q&A

6.

SUMMARY

Corporate strategy, and future direction – Johan Wäborg, Anna Gallon

Finance and shareholders
Direction and opportunities to enhance value
Summary

Open Q&A session